BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DEMENTIA RESEARCHER - ECPv6.14.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DEMENTIA RESEARCHER
X-ORIGINAL-URL:https://www.dementiaresearcher.nihr.ac.uk
X-WR-CALDESC:Events for DEMENTIA RESEARCHER
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20261025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260922
DTEND;VALUE=DATE:20260925
DTSTAMP:20260803T122325
CREATED:20260714T113336Z
LAST-MODIFIED:20260714T113354Z
UID:10002318-1790035200-1790294399@www.dementiaresearcher.nihr.ac.uk
SUMMARY:2026: Biomarker Strategies for FTD Clinical Trials
DESCRIPTION:AFTD is dedicated to improving the lives of families coping with FTD and to advancing research into effective treatments and a cure. The FTD Research Roundtable provides a precompetitive space for biopharmaceutical companies to partner and advance drug development for FTD\, with input from regulators and scientific leaders\, all of whom share a common interest in eliminating barriers to success in FTD clinical trials. If you are working on FTD drug development or a related field and you think that you should participate in the Roundtable\, please get in touch with research@theaftd.org. \nThere has been immense growth in companies focusing on FTD drug development. However\, all companies face similar challenges in FTD drug development. AFTD and scientific leaders are seeking to provide a space in which industry can have precompetitive discussions on FTD clinical trial barriers\, seeking solutions\, proposing best practices and ultimately enable FTD drug development in the past several years. As a result\, the FTD Research Roundtable was developed. \nEach program is selected and designed based upon the priorities of the Steering Committee\, with insight from regulators\, scientific leaders\, and advocates. \n2026: Biomarker Strategies for FTD Clinical Trials\n\nDate: September 22-24\, 2026 \nAgenda: Coming soon \nLeadership Committee: \n\nHoward “Howie” Rosen\, MD\, Academic Co-Chair\nGary Romano\, MD\, PhD\, Industry Co-Chair\nCarmela Tartaglia\, MD\, FRCPC\, Academic Chair-Elect\nRichard Tsai\, MD\, MBA\, Industry Chair-Elect\nMichelle Campbell\, PhD\, US Food & Drug Administration\, Division of Neuroscience\nSteffen Thirstrup\, MD\, PhD\, European Medicines Agency\nGlenn Harris\, PhD\, Rainwater Charitable Foundation\nPenny Dacks\, PhD\, AFTD\nJulia Pierrat\, FTD Family Advocate\n\nSteering Committee Members \n\n\nAcelot\nAFTD\nAlexion\nAviadoBio\nBluefield Project to Cure FTD\nCoya Therapeutics\nCritical Path Institute\nDenali Therapeutics\nEuropean Medicines Agency\nOrchard Therapeutics\nOtsuka\nPassage Bio\nRainwater Charitable Foundation\nUS Food & Drug Administration\nVectorY Therapeutics\n\n\nWebsite – https://www.theaftd.org/for-researchers/ftsg/
URL:https://www.dementiaresearcher.nihr.ac.uk/event/2026-biomarker-strategies-for-ftd-clinical-trials/
LOCATION:In-person and Online\, Harvard University\, Boston Campus\, 25 Shattuck St\, Boston\, MA 02115\, United States
CATEGORIES:Workshop
ATTACH;FMTTYPE=image/jpeg:https://www.dementiaresearcher.nihr.ac.uk/wp-content/uploads/2022/01/AFTD-e1641552368858.jpg
GEO:42.336902;-71.1034769
X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=In-person and Online Harvard University Boston Campus 25 Shattuck St Boston MA 02115 United States;X-APPLE-RADIUS=500;X-TITLE=Harvard University\, Boston Campus\, 25 Shattuck St:geo:-71.1034769,42.336902
END:VEVENT
END:VCALENDAR